biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 6.8

an Open Access Journal by MDPI

Hybrid Nanoplatforms for Theranostics Nanomedicine

Guest Editor:

Dr. Nanasaheb Thorat
Nuffield Department of Women's & Reproductive Health, Medical Science Division, University of Oxford, Oxford, UK

Deadline for manuscript submissions:
closed (31 July 2021)

Message from the Guest Editor

Dear Colleagues,

Nanomedicine, the therapeutic branch of nanotechnology, has reached next generation clinical advances, and many nanomedicine products have been approved for cancer and infectious disease therapies. Hybrid nanoplatforms are capable of performing additional therapeutic modality in cancer and infectious disease management. The therapeutic modalities include early detection of the diseased cells, disease diagnosis, drug loading and delivery, external and internal stimuli responsive drug delivery, therapy, and therapy monitoring. A number of hybrid nanoplatforms have been developed to fight cancer and deadly pathogens; these hybrid nanoplatform include organic nanostructures, polymers, liposomes, lipids, inorganic nanostructures, gold nanoparticles, magnetic materials, silica nanoparticles, silver nanoparticles, titanium dioxide nanoparticles, biomolecules, protein, DNA nanostructures, antimicrobial peptides, metallic nanoparticles, and antiviral hybrid platforms.

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 6.8

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI